Rhythm expects to dose first Phase III bivamelagon HO patients in January as it commits to $350M royalty buy-down
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Health & Medicine
Pest outbreak forces destruction of 52 tonnes of avocados across 4 states
The culprit is the avocado seed weevil (Curculionidae), a snout beetle that penetrates the skin and lays one or two eggs inside the fruit, from which the larvae push through to the seed where they…
Brain Injury Creates Musical Genius; Long COVID Improvement; Dementia and Delirium
(MedPage Today) -- The New York Times detailed the story of Edward Freytag, whose traumatic brain injury made him a musical genius.
Breast cancer atlas reveals hidden subtypes to help chart course for precision oncology
A new molecular map of breast cancer has identified novel forms of the disease and provides a foundation for selecting personalized treatments guided by a tumor's molecular characteristics rather than…
Precision Automation Meets Biology
In this GEN podcast, a cellular workflow automation specialist from Molecular Devices explores what precision automation means for working biologists and how purpose-built instruments, software, and…
Man charged with mailing hundreds of letters containing powder to officials ahead of the election
Federal authorities charged an Oklahoma City man with sending hundreds of letters containing white powder and ominous warnings about treason to public officials ahead of the 2024 and 2026 elections.
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.